Macrophages and acylcarnitines: New players in aspirin-exacerbated respiratory disease? - 04/02/21
Doi : 10.1016/j.jaci.2020.09.040
Tanya M. Laidlaw, MD ⁎ 
, Barbara Balestrieri, MD
, Barbara Balestrieri, MD Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass
∗Corresponding author: Tanya M. Laidlaw, MD, Brigham and Women’s Hospital, 60 Fenwood Rd, Building of Transformative Medicine, Rm 5002M, Boston, MA 02115.Brigham and Women’s Hospital60 Fenwood RdBuilding of Transformative MedicineRm 5002MBostonMA02115
Key words : AERD, macrophages, type 2 inflammation, acylcarnitines, fatty acids, eicosanoids
Il testo completo di questo articolo è disponibile in PDF.
| Disclosure of potential conflict of interest: T. M. Laidlaw has served on scientific advisory boards for GlaxoSmithKline and Sanofi-Genzyme, Optinose, and Regeneron. B. Balestrieri has no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 147 - N° 2
P. 498-500 - Febbraio 2021 Ritorno al numero
Articolo precedente
- 2020: The year in review
- Zuhair K. Ballas
- Eicosanoid relay: Epithelial and mast cell transmetabolism in AERD
- Daniel F. Dwyer
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?